Yanis A. Boumber, Ph.D.
Affiliations: | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Molecular BiologyGoogle:
"Yanis Boumber"Parents
Sign in to add mentor| Jean-Pierre Issa | grad student | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston | |
| (An Sp1/Sp3 site polymorphism associated with hypermethylation of the candidate tumor suppressor gene RIL in cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Topchu I, Bychkov I, Gursel D, et al. (2023) NSD1 supports cell growth and regulates autophagy in HPV-negative head and neck squamous cell carcinoma. Biorxiv : the Preprint Server For Biology |
| Bychkov I, Deneka A, Topchu I, et al. (2023) Musashi-2 (MSI2) regulation of DNA damage response in lung cancer. Biorxiv : the Preprint Server For Biology |
| Bychkov I, Topchu I, Makhov P, et al. (2023) Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer. Cancers. 15 |
| Bychkov I, Topchu I, Makhov P, et al. (2023) Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer. Biorxiv : the Preprint Server For Biology |
| Khaddour K, Felipe Fernandez M, Khabibov M, et al. (2022) The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. Cancers. 14 |
| Topchu I, Pangeni RP, Bychkov I, et al. (2022) The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. Cellular and Molecular Life Sciences : Cmls. 79: 285 |
| Topchu I, Karnaukhov N, Mazitova A, et al. (2021) Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). Journal of Thoracic Disease. 13: 1370-1379 |
| Deneka A, Kharin L, Karnaukhov NS, et al. (2020) Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38 |
| Bodor JN, Boumber Y, Borghaei H. (2019) Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer |
| Deneka AY, Boumber Y, Beck T, et al. (2019) Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers. 11 |